Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.21M$7.21Mderived+133.0% vs Q4 2022 Net Income-$19.61M-$19.61MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$21,357,000N/M Operating Cash Flowderived-$23,766,000N/M Free Cash Flowderived-$24,235,000N/M Margins · derivedOperating margin-296.2%+306.4 pt vs Q4 2022
Net margin-272.0%+333.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 6, 2024 · 66 d after period end